PUBLISHER: TechNavio | PRODUCT CODE: 1911263
PUBLISHER: TechNavio | PRODUCT CODE: 1911263
The global menstrual drugs market is forecasted to grow by USD 4597.4 mn during 2025-2030, accelerating at a CAGR of 8.4% during the forecast period. The report on the global menstrual drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing global awareness and improved diagnosis of menstrual health disorders, substantial pharmaceutical innovation and expansion of treatment portfolio, favorable reimbursement policies and increasing global healthcare expenditure on women health.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2026 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 7.7% |
| CAGR | 8.4% |
| Incremental Value | $4597.4 mn |
Technavio's global menstrual drugs market is segmented as below:
By Type
By Route Of Administration
By Distribution Channel
Geography
This study identifies the ascendancy of non-hormonal treatment modalities as one of the prime reasons driving the global menstrual drugs market growth during the next few years. Also, integration of digital health and pursuit of personalized medicine and strategic focus on disease-modifying therapies over symptomatic relief will lead to sizable demand in the market.
The report on the global menstrual drugs market covers the following areas:
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global menstrual drugs market vendors that include AbbVie Inc., Adorefem, Bayer AG, Cipla Inc., Dr Reddys Laboratories Ltd., GlaxoSmithKline Plc, Haleon Plc, Johnson and Johnson Services, Leeford Healthcare Ltd., Mallinckrodt Plc, Maxwellia Ltd., Perrigo Co. Plc, Pfizer Inc., Reckitt Benckiser Group Plc, Sanofi SA, Sumitomo Chemical Co. Ltd., Teva Pharmaceutical Ltd., The Himalaya Drug Co., Walgreens Boots Alliance Inc., Zydus Lifesciences Ltd.. Also, the global menstrual drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.